LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today reported financial results for the first quarter ended March 31, 2007.
“We already have achieved several key milestones in the early part of this year, including the positive results from our Phase 1b trial of PRX-07034 and our continued progress in advancing our pipeline and building our internal corporate structure,” said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. “We believe EPIX is well positioned for near-term catalysts and the achievement of key corporate clinical milestones in 2007.”
